Apogee Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
02 Enero 2024 - 6:30AM
Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage
biotechnology company advancing differentiated biologics for the
treatment of atopic dermatitis (AD), asthma, chronic obstructive
pulmonary disease (COPD) and other inflammatory and immunology
(I&I) indications, today announced that Michael Henderson,
M.D., Chief Executive Officer of Apogee, will present at the 42nd
Annual J.P. Morgan Conference on Tuesday, January 9, 2024 at 7:30
a.m. P.T. / 10:30 a.m. E.T.
A live and archived webcast of the presentation will be
available via the News & Events page in the Investors section
of the Apogee Therapeutics website.
About Apogee Therapeutics
Apogee Therapeutics is a clinical-stage biotechnology company
seeking to develop differentiated biologics for the treatment of
atopic dermatitis (AD), asthma, chronic obstructive pulmonary
disease (COPD) and other inflammatory and immunology indications
with high unmet need. Apogee’s antibody programs are designed to
overcome limitations of existing therapies by targeting
well-established mechanisms of action and incorporating advanced
antibody engineering properties, including half-life extension. The
company’s two most advanced programs are APG777 and APG808, which
are being initially developed for the treatment of AD and COPD,
respectively. Based on a broad pipeline and depth of expertise, the
company believes it can deliver value and meaningful benefit to
patients underserved by today’s standard of care. For more
information, please visit www.apogeetherapeutics.com.
Investor Contacts:
Noel KurdiVP of Investor Relations Apogee
Therapeuticsnoel.kurdi@apogeetherapeutics.com
Media Contact:
Dan Budwick 1AB Mediadan@1abmedia.com
Apogee Therapeutics (NASDAQ:APGE)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Apogee Therapeutics (NASDAQ:APGE)
Gráfica de Acción Histórica
De May 2023 a May 2024